Adagene Inc   Report issue

For profit Phase 1 Phase 2
Founded: Suzhou China (2012)

Organization Overview

First Clinical Trial
2018
NCT03707093
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Adagene Inc | Adagene (Suzhou) Limited

Active Ingredients

Drugs in Phase 2 Trials (1)

adg106 (3 trials)

Drugs in Phase 1 Trials (2)

adg116 (2 trials)

adg126 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Lymphoma, Non-Hodgkin (Phase 1)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 3